focus -WSS

focus

author：leisure time 2025-10-06 07:55:02 - browse：56

Priscilla Chan and Mark Zuckerberg on stage, virtually, at the 2023 STAT Summit. STAT

Mark Zuckerberg and Priscilla Chan sit atop a fortune that is currently valued at $113 billion, and they’ve promised to give almost all of it away. Their philanthropic funding group, the Chan Zuckerberg Initiative, is committed to investing in an array of fields, including science, education, housing insecurity, and expanding access to startup capital to entrepreneurs of color.

In 2015, when the self-described science nerds pledged 99 percent of their Facebook fortune to philanthropic causes over their lifetimes, they did not specify how they might spread their wealth. But at the STAT Summit on Wednesday, the couple went further in describing their goals, doubling down on science.

“The science piece is a huge, huge part of that,” Zuckerberg said when asked about his spending plans. “I would imagine that if the company continues doing well that we will have $50 billion or more over time to put into this kind of work, but we want that to compound and grow over time as we get more confidence in the model.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： How to protect patients from sexual assault

WSS

UnitedHealth’s Optum accused of antitrust violations in California

Humana sues Biden admin over Medicare Advantage audit rule

House transparency, PBM reform bill gains bipartisan support

Flagship Pioneering launches a new biotech in two countries

With clinical trial data readouts, here's how to spot spin

BIO selects John Crowley as new CEO

Wikipedia

focus

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Listen: Biogen's potential pivot, & Illumina's next chapter

Duchenne breakthrough therapy leaves behind pioneering families

BIO selects John Crowley as new CEO

BioMarin wins approval for gene therapy to treat hemophilia A

How to fix cancer clinical trials' diversity problem

Activists slam private health insurers over coverage restrictions

What American doctors can learn from their Israeli counterparts

ChatGPT in medicine: STAT answers readers' burning questions

Takeda, Janssen join wearable maker to measure scratching

focus

A new House health package & hospitals’ new site

Covid hospitalizations on the rise, Humana says

FDA investigates CAR

Snackable artificial intelligence, expert AI, and the pharma industry

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Flagship Pioneering launches a new biotech in two countries

leisure time

entertainment

focus

hotspot